Abstract
Background: Abdominal aortic aneurysm (AAA), a progressive segmental abdominal aortic dilation, is associated with high mortality. AAA is characterized by inflammation, smooth muscle cell (SMC) depletion and extracellular matrix (ECM) degradation. Surgical intervention and endovascular therapy are recommended to prevent rupture of large AAAs. Unfortunately, there is no reliable pharmacological agent available to limit AAA expansion. In the past decades, extensive investigations and a body of ongoing clinical trials aimed at defining potent treatments to inhibit and even regress AAA growth.
Conclusion: In this review, we summarized recent progress of potential strategies, particularly macrolides, tetracyclines, statins, angiotensin converting enzyme inhibitors, angiotensin receptor blocker, corticosteroid, anti-platelet drugs and mast cell stabilizers. We also consider recently identified novel molecular targets, which have potential to be translated into clinical practice in the future.
Keywords: Abdominal aortic aneurysm, clinical trials, medical treatment, pharmacological therapy, molecular target, disease.
Current Vascular Pharmacology
Title:Pharmacological Therapy of Abdominal Aortic Aneurysm: An Update
Volume: 16 Issue: 2
Author(s): Yi-dong Wang, Zhen-jie Liu, Jun Ren and Mei-Xiang Xiang*
Affiliation:
- Department of Cardiology, Second Affiliated Hospital of Zhejiang University School of Medicine, Cardiovascular Key Lab of Zhejiang Province, #88 Jiefang Road, Hangzhou, Zhejiang, 310009,China
Keywords: Abdominal aortic aneurysm, clinical trials, medical treatment, pharmacological therapy, molecular target, disease.
Abstract: Background: Abdominal aortic aneurysm (AAA), a progressive segmental abdominal aortic dilation, is associated with high mortality. AAA is characterized by inflammation, smooth muscle cell (SMC) depletion and extracellular matrix (ECM) degradation. Surgical intervention and endovascular therapy are recommended to prevent rupture of large AAAs. Unfortunately, there is no reliable pharmacological agent available to limit AAA expansion. In the past decades, extensive investigations and a body of ongoing clinical trials aimed at defining potent treatments to inhibit and even regress AAA growth.
Conclusion: In this review, we summarized recent progress of potential strategies, particularly macrolides, tetracyclines, statins, angiotensin converting enzyme inhibitors, angiotensin receptor blocker, corticosteroid, anti-platelet drugs and mast cell stabilizers. We also consider recently identified novel molecular targets, which have potential to be translated into clinical practice in the future.
Export Options
About this article
Cite this article as:
Wang Yi-dong , Liu Zhen-jie , Ren Jun and Xiang Mei-Xiang *, Pharmacological Therapy of Abdominal Aortic Aneurysm: An Update, Current Vascular Pharmacology 2018; 16 (2) . https://dx.doi.org/10.2174/1570161115666170413145705
DOI https://dx.doi.org/10.2174/1570161115666170413145705 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
Ischemic Cardiovascular Diseases: Mechanisms, Diagnosis and Therapy
Ischemic cardiovascular disease includes myocardial infarction, coronary atherosclerotic heart disease, angina pectoris, etc., constitute the leading cause of patient mortality by preventing tissues from getting sufficient oxygen and nutrients. Ischemic heart disease, as a clinical condition, is characterized by myocardial ischemia, causing an imbalance between myocardial blood supply and demand, ...read more
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Intraoperative Magnetic Resonance Imaging
Current Medical Imaging Anti-epileptic Drug (AED) Use in Subarachnoid Hemorrhage (SAH) and Intracranial Hemorrhage (ICH)
Current Pharmaceutical Design Type 1 Diabetes Mellitus - Risk Factor for Cardiovascular Disease Morbidity and Mortality
Current Diabetes Reviews Secondary Hypertension: The Ways of Management
Current Vascular Pharmacology Occurrence and Clinical Impact of Microembolic Signals (MES) in Patients with Chronic Cardiac Diseases and Atheroaortic Plaques - A Systematic Review
Current Vascular Pharmacology Hyperuricaemia and Non-Alcoholic Fatty Liver Disease (NAFLD): A Relationship with Implications for Vascular Risk?
Current Vascular Pharmacology Pharmacological Regulation of Dyslipoproteinaemia in Insulin Resistant States
Current Vascular Pharmacology Patient-Specific Modeling and Multi-Scale Blood Simulation for Computational Hemodynamic Study on the Human Cerebrovascular System
Current Pharmaceutical Biotechnology Renal Nerve Ablation for Hypertensive Patients with Chronic Kidney Disease
Current Vascular Pharmacology Current Management of Traumatic Rupture of the Descending Thoracic Aorta
Current Cardiology Reviews Role of the LDL Receptor-Related Protein 1 in Regulating Protease Activity and Signaling Pathways in the Vasculature
Current Drug Targets Beneficial Extracardiac Effects of Cardiovascular Medications
Current Cardiology Reviews Physical Function and Exercise in Older Patients with Cardiovascular and Respiratory Conditions
Current Pharmaceutical Design Adrenergic and V1-ergic Agonists/Antagonists Affecting Recovery from Brain Trauma in the Lund Project Act on Astrocytes
Current Signal Transduction Therapy Strategies for the Preparation of Bifunctional Gadolinium(III) Chelators
Current Organic Synthesis Advanced Therapies For End-Stage Heart Failure
Current Cardiology Reviews Matrix Metalloproteinases as Potential Targets in the Venous Dilation Associated with Varicose Veins
Current Drug Targets The Roles of MicroRNAs in Atherosclerosis
Current Medicinal Chemistry Interventional Radiology in Paediatrics
Current Pediatric Reviews Antithrombotic Therapy in Cardiac Embolism
Current Cardiology Reviews